BTB JapanCompany Overview
as of June 2017

I. Facts of the Company
II. Executive Officers & Advisors
III. Business Objective
IV. Existing Business
V. Contact Information

I. Facts of the Company
1. Name2. Location

BTB Japan, Inc.
4F Le Gratte-Ciel Bldg. 3, 5-22-3 Shinbashi, Minato-ku,
Tokyo 105-0004, Japan
3. Contact Person CEO, Isao Kikuchi
4. Establishment
Sept 3, 2012
5. Employees & Retained Advisors; 7
6. Pre-History;
May 2005

Masa Japan as the agent for USA Life Science Fund named MLSV (Masa Life ScienceVentures) has started cordination job to invite and to be joined by Japanese investors
as limited partners. 5 Japanese investors have participated.

March 2009

The activity of Masa Japan has been transferred to Acube Inc.

Oct. 2009

Started to work as sole importer of USA Maxcyte Cell Transfection System (STX)Oct. 2010

As the agent for USA Life Science Fund named Epidarex started cordination job toinvite and to be joined by Japanese investors as limited partners.
3 Japanese investors have participated.

August 2011

Started to work as an agent for Germany Cevec Pharmaceutical to introduce Human
Amniotic Cell (CAP & CAP-T)

Sept 2012

Bio-Technology Business is transferred from Acube Inc. to newly establishedcompany named BTB Japan Inc.

2II.a Executive Officers & Advisors in Japan
Name

Title/Current/Former Affiliation and Expertise

Kikuchi, I.

CEO: Former general manager of Marubeni Corporation (one of major Japanese tradingcompanies) then worked for Masa Inc. and Acube Inc. (biotech consulting firms) .

Yamada, Y.

Advisor, PhD(Pharmacology): Former head of a laboratory at Taiho Pharma (a Otsuka
Pharma group)

Ito, K

Advisor, PhD(Pharmacology): Former bio-tech analyst in Nikko Antfactory K.K, a VC and now
working as CEO at a JPN bio venture company

Nakayoshi, H.

Advisor, PhD(virology): Former director of Nomura BioScience Institute, the first person
who introduced a clinical CRO to JPN.

Mori, T.

Advisor, PhD(Pharmacology): Former head of a laboratory at Ono Pharma

Itaya, H.

Advisor, Former Affymetrix Japan Representative and Former general manager at Hitachi
Chemical Industries, Japan3

II.b Representative and Advisors in USA and China
Name

Title/Current/Former Affiliation and Expertise

MichaelHertzberg

Representative in USA; President, Global Trade Strategies International, LLC (medicaldevice international business development company) and Vice President, Finnish
Technology Development, LLC,
International Trade Law and Entrepreneurial International Business Development
backgroundEugene Bauer

Advisor, MD; Founder and Chief Medical Officer at Dermira, Inc. (Dermatology) Former
Professor(Emeritus) in the school of Medicine at Stanford Univ.

Chuck Hewitt

Advisor, PhD: CEO and Co-Founder of ImmunO4 LLC. (Chemiluminescent Substrate) ,Managing Partner of Epic BioVentures, LLC., Former CEO of BioFX Laboratories Inc.

Kirby S. Black

Advisor, PhD(Immunology/Cell Biology), Managing Partner, Epic BioVentures, LLC. Former
Professor of Biotechnology, Kennesaw State Univ.

Yongping Yu

Representative in China; PhD(Chemistry), Professor and Director Academic Committee atCollege of Pharmaceutical Sciences, Zhejiang, China

4

III. Business Objective
As an intermediate agent, BTB Japan has been focusing on
innovative products/technologies in the life-science field.
1. To US and EU bio-ventures; cost effective inroad into the JPN market.
2. To JPN pharmaceutical companies; providing information andassistance regarding innovative technologies and also drug candidates
or seeds.
3. To JPN bio-ventures; providing information and assistance oninnovative technologies as well as on possible licensing-out/collaboration opportunities with overseas.
4. To JPN academia; providing information and assistance on innovativetechnologies and also drug candidates or seeds for their drug
discovering and clinical development.
5. To JPN distributor for medical system/equipment/device; providing
information and assistance on innovative technologies as well as on
possible licensing /collaboration opportunities with overseas.
5

IV. Existing Business（１） Technology brokerage business(1), - the protein productionrelated technologies.
We have established a relationship with JPN TOP20 pharmaceutical companies
and Ab bio-ventures through the existing business and are extending to academia.
Bio-Ventures

Proprietary technologies

URL

MaxCyte, Inc.,
MD, USA

Scalable transfection apparatus (STX®) up
to 1010 cells and reagents

www.maxcyte.com

CEVEC Pharmaceuticals
GmbH, Kӧln, Germany

Human amniocyte-derived cell line (CAP®)
for protein and viral production

www.cevec.com

Selexis SA,
Geneva, Switzerland

SUREtechnology® platform fordevelopment of cell-lines with stable andhigh-efficient expression

www.selexis.com

6 Technology brokerage business(2), - Seeds for unique therapeutics & diagnostics
Torrey Pines Institutefor Molecular Studies(TPIMS), San Diego, CA
and Port St. Lucie, FL

The compound library collection of over 30 million
www.tpims.org/
drug-like compounds and billions of peptides, arrangedin the positional scanning format which allows for thetesting of millions of compounds using only hundreds ofsamples.

NuvOx Pharma,
Tucson, Arizona

Innovative platform of DDFP (dodecafluoropentane)based oxygen therapeutics to treat a host of humanconditions.

www.nuvoxpharma.com/SAJE Pharma,
Baltimore, MD

Small molecule drugs regulate nitrosylation byinhibiting GSNOR (S-nitrosoglutathione reductase) andthe resultant increase of GSNO(a storage form ofNO) which increases nitrosylation of accessible
cysteines on key signaling proteins.

www.sajepharma.com/

Cellectar Biosciences,Madison, WI

The product candidates are built on a novel, cancer and cellectarbiosciences.cocancer stem cell-targeting delivery and retentionm/platform of optimized phospholipid ether analogs (PLEs).

7 Technology brokerage business(2), continued- Seeds for unique therapeutics & diagnostics
ImmunO4, Westminster, Innovative and Efficient Chemiluminescent SubstrateMDwww.immuno4.com

Motif Bio, UK & NewYork, USA

www.motifbio.com/

Iclaprim, Phase III antibiotic against infections caused
by multi-drug-resistant bacteria

Nolla Antimicrobial Ltd., Silver Polymer chain 0.5 nanometers thickness having
Helsinki, Finland
10 times more antimicrobial than the any other form ofsilver; Usage is broad. Drug; Herpes, Eczame, Others;
Sanitizer, Paper Coating, Textile Coating, Laundry, Foot
Deodorizer, Cosmetics (Deodorant, Hygiene andShaving),Mycoplasma,

www.nollaantimicrobial.com/The Sage Group,Clinton, NJ, USA

Collaborative consulting with USA based business andinvestment consulting firm for its client and Japan suchas; arGentis; Mid stage Orphan Drug treatment(ARG201 and ROT1) for dcSSc (Diffuse Late Stage
Systemic Scleroderma) and IZUN; Curasite Wound CareTreatment (Anti-Inflammatory & Tissue Repair)www.thesagegroup.com/

Assuage
Pharmaceuticals

Developing drug with superior safety and efficacy than www.assuagepharma.c
existing smoking cessation products; future products for om/
8other addictions.

IV. Existing Business（2）Service businessEpidarex Capital( www.epidarex.com) ; Started in October 2010. To
introduce to the investors Bio-Technology developed mainly in USA
and Europe is the major purpose. Such introduction is very specificto fund investors and are focused on their interests. The objective
is to develop large distribution opportunities utilizing the investors'
global networks. Support for Licensing and Distribution Agreement
is also provided.

9V. Contact Information
For more information please contact:
Isao Kikuchi

BTB Japan, Inc.
4F Le Gratte-Ciel Bldg.3, 5-22-3 Shinbashi,Minato-ku, Tokyo 105-0004, Japankikuchi@btbjapan.com
Tel/Fax: +81-3-6459-0258

http://www.btbjapan.com

10